Rexahn Pharmaceuticals (RNN)
Rexahn Pharmaceuticals Key Statistics
Pro Data ExportCurrent Valuation
Dividends and Shares
| Dividend | |
| Dividend Yield | 0.00% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | |
| Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin | |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 10.15 |
| Debt to Equity Ratio | 0.00 |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -5.12% |
| Year to Date Stock Returns | 8.51% |
| 1 Year Stock Returns | -68.86% |
| 3 Year Stock Returns | -64.21% |
| 52 Week High | 1.36 |
| 52 Week Low | 0.342 |
Income Statement
Cash Flow Statement
| Cash Investing TTM | 2.568M |
| Cash Financing TTM | |
| Cash Operations TTM | -15.02M |
| Capital Expenditures | 0.00 |
Share Statistics
| Shares Outstanding | 95.35M |
Balance Sheet
| Cash and ST Investments | 10.05M |
| Total Assets | 11.71M |
| Liabilities | 3.052M |
| Book Value | 8.658M |
| Book Value per Share | 0.0908 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 0.00 |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
You may also be interested in these RNN related companies
RNN News
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anti-Cancer Compound RX-3117
May 30, 8:00AM Business Wire
May 30, 8:00AM Business Wire
Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA
May 08, 8:02AM Benzinga
May 08, 8:02AM Benzinga
Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds
Apr 30, 8:00AM Business Wire
Apr 30, 8:00AM Business Wire
$RNN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3XOX
about 35 days ago by MarketBrief
about 35 days ago by MarketBrief
Rexahn Pharmaceuticals to Present Data on Novel Anti-Cancer Small Molecule RX-3117 at AACR 103rd Annual Meeting
Mar 27, 8:00AM Business Wire
Mar 27, 8:00AM Business Wire
Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117
Mar 13, 8:02AM Benzinga
Mar 13, 8:02AM Benzinga
Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds
Jan 25, 8:00AM Benzinga
Jan 25, 8:00AM Benzinga
Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform
Jan 18, 12:44PM Benzinga
Jan 18, 12:44PM Benzinga
Rexahn Pharmaceuticals (RNN) Receives Approval in Europe to Conduct a First-in-Human Trial of RX-3117
Jan 18, 8:03AM Street Insider
Jan 18, 8:03AM Street Insider
Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests
Nov 09, 8:16AM Marketwire
Nov 09, 8:16AM Marketwire
Rexahn Pharmaceuticals (RNN) Offers Results from Phase II Trial of Serdaxin for Major Depressive Disorder
Nov 04, 8:26AM Street Insider
Nov 04, 8:26AM Street Insider
Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin® as Treatment for Major Depressive Disorder
Nov 04, 8:00AM Business Wire
Nov 04, 8:00AM Business Wire
Rexahn Pharmaceuticals granted U.S. patent for isoquinolinamine compounds
Oct 12, 8:01AM FlyOnTheWall
Oct 12, 8:01AM FlyOnTheWall
Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds
Oct 12, 8:00AM Business Wire
Oct 12, 8:00AM Business Wire
Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin®
Oct 03, 8:00AM Business Wire
Oct 03, 8:00AM Business Wire
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
Sep 08, 8:00AM Business Wire
Sep 08, 8:00AM Business Wire
Rexahn Pharmaceuticals announces patent for neurotherapeutic compositions
Aug 08, 9:03AM FlyOnTheWall
Aug 08, 9:03AM FlyOnTheWall
$RNN http://chart.ly/bxxaome Do not like the Company at all; however they have done some excellent P&D. very tight range.
about 307 days ago by Wiserguy1971
about 307 days ago by Wiserguy1971
sold the $RNN I've been holding for at least a month at 1.21 for small loss. don't like the large shelf offering
about 343 days ago by LitheLyricist
about 343 days ago by LitheLyricist
RT @ABtrader $RNN sees completing Trial, announcing Prelim Results before Yr End = Should see some big action today.
about 344 days ago by epollux
about 344 days ago by epollux
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| RNN | 0.408 | +0.00 | +0.00% | 38.90M |
| RNIN | 0.76 | +0.01 | +1.33% | 17.46M |
| RNF | 23.78 | +0.38 | +1.62% | |
| RNET | 15.33 | +0.13 | +0.86% | 234.69M |
| RNE | 13.72 | -0.25 | -1.79% | |
| RMTR | 1.86 | -0.10 | -5.10% | 69.24M |
| RMT | 8.70 | -0.02 | -0.23% | |
| RMKR | 0.65 | +0.02 | +3.14% | 17.43M |
| RMD | 30.70 | -0.42 | -1.35% | 4.487B |
| RMCF | 10.45 | -0.01 | -0.10% | 64.05M |
